Cory Bentley is a co-founder of Abintus and serves as SVP co-lead R&D. Dr. Bentley has over 15 years of experience in translational science focused on oncology and immuno-oncology. Prior to founding Abintus, Dr. Bentley was Director of Translational Research at Tocagen where she helped pioneer in vivo reprogramming of immune cells. She also has extensive experience in antibody discovery and development from her roles as Chief Scientific Officer and co-founder at RIFT Biotherapeutics, which focused on tumor microenvironment challenges, and Director of Discovery at Sevion Therapeutics. Dr. Bentley completed postdoctoral fellowships at Brown University and the The Genomics Institute of the Novartis Research Foundation. She holds a Ph.D. in Biomedical Sciences from UC San Diego, an MBA from the Rady School of Management at UC San Diego, and a BA in Chemistry from Occidental College.